CHINA COHORT
Overview of China cohort
Most of the participants in the study from China joined the study later than the
participants from the rest of the world during Part 2. This group of participants is
known as the “China cohort”.
What treatments did the participants get during the China
cohort?
There were 14 participants in the China cohort. One participant did
not get any study treatment. The other 13 participants got 1 of the
following:
X durvalumab
X tremelimumab
X a combination of durvalumab and tremelimumab, then durvalumab
on its own
What were the results of the China cohort?
The main questions the researchers wanted to answer in the China
cohort were:
X What signs and symptoms did the participants have during the
China cohort?
The most common symptom that may or may not be caused by
the study drugs that the participants had during the China cohort
was an increase in a liver protein called AST.
X What medical problems happened during the China cohort?
There were 84.6% of participants in the China cohort who had
medical problems that the study doctors thought might be related
to the study drugs during the study. The most common medical
problem was an increase in a liver protein called AST.
More details about the answers to these questions can be found later in
this summary.
25 | Clinical Study Results